» Articles » PMID: 15912383

A Literature Review on Off-label Drug Use in Children

Overview
Journal Eur J Pediatr
Specialty Pediatrics
Date 2005 May 25
PMID 15912383
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The aim was to compare results of studies performed in different settings worldwide and identify common therapeutic areas to allow for focused interventions, because off-label drug use can be a measure of the lack of knowledge concerning paediatric treatments. A secondary objective was to provide a brief review of efforts to date. A literature review of articles on off-label and unlicensed drug use in children involving general prescription samples was performed using Medline and Embase. In all, 30 studies from 1985-2004 were included. Eleven involved paediatric hospital wards, seven neonatal hospital wards, and 12 the community setting. The off-label and unlicensed classification methods varied, making results difficult to compare. In general, off-label/unlicensed prescription rates ranged from 11%-80%, and higher rates were found in younger versus older patients and in the hospital versus community settings. On the paediatric hospital wards, off-label/unlicensed prescriptions ranged from 16%-62% and most often concerned acetaminophen, cisapride, chloral hydrate, and salbutamol. In the neonatal wards, rates ranged from 55%-80% and often involved caffeine. In the community setting, rates ranged from 11%-37% and the most commonly implicated drugs were salbutamol and amoxicillin.

Conclusion: A lack of harmonization between the evidence, the information available to doctors, and its use in clinical practice exists and this is part of the reason off-label therapies are so common. Attempts have been made to improve knowledge concerning paediatric treatments, but more focused interventions are needed, also taking into consideration this lack of harmonization.

Citing Articles

Pediatric-Specific Drug Loss Issue in Japan: Comparison of Pediatric Development Status Between Japan and the United States.

Osako R, Matsumaru N, Tsukamoto K Ther Innov Regul Sci. 2024; 59(1):142-149.

PMID: 39441417 DOI: 10.1007/s43441-024-00714-6.


Formulation and Evaluation of Polysaccharide Microparticles for the Controlled Release of Propranolol Hydrochloride.

Stojmenovski A, Gataric B, Vucen S, Railic M, Krstonosic V, Kukobat R Pharmaceutics. 2024; 16(6).

PMID: 38931909 PMC: 11207763. DOI: 10.3390/pharmaceutics16060788.


Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories.

Chen X, Ou S, Luo J, He Z, Jiang Q Front Pharmacol. 2024; 15:1374549.

PMID: 38898925 PMC: 11186405. DOI: 10.3389/fphar.2024.1374549.


Prescription of off-label and unlicensed medication for newborns hospitalized in the Intensive Care Unit.

Santos L, Santos J, Moehlecke Iser B, Kock K, Bo K Rev Paul Pediatr. 2023; 42:e2023023.

PMID: 37729244 PMC: 10508043. DOI: 10.1590/1984-0462/2024/42/2023023.


Optimizing therapeutic decision-making for off-label medicines use: A scoping review and consensus recommendations for improving practice and research.

Gazarian M, Horton D, Carleton B, Kinlaw A, Bushnell G, Czaja A Pharmacoepidemiol Drug Saf. 2023; 32(11):1200-1222.

PMID: 37208845 PMC: 10543391. DOI: 10.1002/pds.5640.


References
1.
McKinzie J, Wright S, Wrenn K . Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines?. Am J Emerg Med. 1997; 15(2):118-21. DOI: 10.1016/s0735-6757(97)90079-6. View

2.
Turner S, Longworth A, Nunn A, Choonara I . Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998; 316(7128):343-5. PMC: 2665567. DOI: 10.1136/bmj.316.7128.343. View

3.
Ufer M, Kimland E, Bergman U . Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004; 13(3):147-52. DOI: 10.1002/pds.858. View

4.
Ufer M, Rane A, Karlsson A, Kimland E, Bergman U . Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol. 2003; 58(11):779-83. DOI: 10.1007/s00228-003-0560-z. View

5.
Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P . A novel scheme for the reporting of adverse drug reactions. Arch Dis Child. 2001; 84(4):337-9. PMC: 1718721. DOI: 10.1136/adc.84.4.337. View